Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: An Adoptive Cellular Therapy for Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From Matched HLA Donors
Latest Information Update: 30 May 2025
At a glance
- Drugs NEXI 001 (Primary) ; Cyclophosphamide; Decitabine; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
Most Recent Events
- 25 May 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jan 2025 Planned initiation date changed from 7 Dec 2024 to 7 Jun 2025.
- 29 Aug 2024 New trial record